Review



human hcc cell lines c3a  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC human hcc cell lines c3a
    CAIX and CAXII expression and functional inhibition in <t>HCC</t> cell lines. The indicated HCC cell lines were cultured under either normoxic (N = 21% O 2 ) or hypoxic (H = 1% O 2 ) conditions for 72 h and were analyzed as indicated below. (A) The protein expression of CAIX, CAXII and vinculin was assessed by western blotting in cell lysates of the <t>C3A,</t> PLC/PRF/5 and SNU-449 cell lines. The cell surface expression of CAIX (B) and CAXII (C) was evaluated by flow cytometry. The number in each histogram plot shows the percentage of cells positive for the indicated markers (filled histograms) evaluated with respect to the corresponding secondary antibody (black line). Representative histograms from three independent experiments are shown. (D) The cellular distribution of CAXII was assessed by confocal laser scanning microscopy under the indicated conditions. Representative micrographs of triple immunofluorescence staining with anti-CAXII (green), anti-WGA (red, detecting the cell membrane) and anti-calnexin (blue, detecting the ER compartment) are reported. Scale bars = 50 μm and = 5 μm for the lower and higher magnification respectively. The cell viability of the HCC cell lines treated with different doses of S4 (µM) (E) and compound 25 (µM) (F) under normoxia (N = 21% O 2 , black triangles) or hypoxia (H = 1% O 2 , white triangles) for 72 h was evaluated using the MTT assay. The data show the percentage of viable cells of the untreated control and represent the mean of six replicate reactions from 3 independent experiments. IC 50 values for S4 were >100 μM for all HCC cell lines grown under normoxic conditions and 57.4, 53.9 and >100 μM for C3 A, PLC/PRF/5 and SNU-449 exposed to hypoxia respectively. For compound 25, C3 A, PLC/PRF/5 and SNU-449 cells grown under normoxia displayed IC 50 values of 198.5, 142.9 and >200 μM respectively. All the HCC cell lines exposed to hypoxia displayed IC 50 values >200 μM for compound 25.
    Human Hcc Cell Lines C3a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 271 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/line-scan+function+in/C3A/pmc05993489-243-1-16
    Average 96 stars, based on 271 article reviews
    human hcc cell lines c3a - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma"

    Article Title: pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma

    Journal: Oncoimmunology

    doi: 10.1080/2162402X.2018.1445452

    CAIX and CAXII expression and functional inhibition in HCC cell lines. The indicated HCC cell lines were cultured under either normoxic (N = 21% O 2 ) or hypoxic (H = 1% O 2 ) conditions for 72 h and were analyzed as indicated below. (A) The protein expression of CAIX, CAXII and vinculin was assessed by western blotting in cell lysates of the C3A, PLC/PRF/5 and SNU-449 cell lines. The cell surface expression of CAIX (B) and CAXII (C) was evaluated by flow cytometry. The number in each histogram plot shows the percentage of cells positive for the indicated markers (filled histograms) evaluated with respect to the corresponding secondary antibody (black line). Representative histograms from three independent experiments are shown. (D) The cellular distribution of CAXII was assessed by confocal laser scanning microscopy under the indicated conditions. Representative micrographs of triple immunofluorescence staining with anti-CAXII (green), anti-WGA (red, detecting the cell membrane) and anti-calnexin (blue, detecting the ER compartment) are reported. Scale bars = 50 μm and = 5 μm for the lower and higher magnification respectively. The cell viability of the HCC cell lines treated with different doses of S4 (µM) (E) and compound 25 (µM) (F) under normoxia (N = 21% O 2 , black triangles) or hypoxia (H = 1% O 2 , white triangles) for 72 h was evaluated using the MTT assay. The data show the percentage of viable cells of the untreated control and represent the mean of six replicate reactions from 3 independent experiments. IC 50 values for S4 were >100 μM for all HCC cell lines grown under normoxic conditions and 57.4, 53.9 and >100 μM for C3 A, PLC/PRF/5 and SNU-449 exposed to hypoxia respectively. For compound 25, C3 A, PLC/PRF/5 and SNU-449 cells grown under normoxia displayed IC 50 values of 198.5, 142.9 and >200 μM respectively. All the HCC cell lines exposed to hypoxia displayed IC 50 values >200 μM for compound 25.
    Figure Legend Snippet: CAIX and CAXII expression and functional inhibition in HCC cell lines. The indicated HCC cell lines were cultured under either normoxic (N = 21% O 2 ) or hypoxic (H = 1% O 2 ) conditions for 72 h and were analyzed as indicated below. (A) The protein expression of CAIX, CAXII and vinculin was assessed by western blotting in cell lysates of the C3A, PLC/PRF/5 and SNU-449 cell lines. The cell surface expression of CAIX (B) and CAXII (C) was evaluated by flow cytometry. The number in each histogram plot shows the percentage of cells positive for the indicated markers (filled histograms) evaluated with respect to the corresponding secondary antibody (black line). Representative histograms from three independent experiments are shown. (D) The cellular distribution of CAXII was assessed by confocal laser scanning microscopy under the indicated conditions. Representative micrographs of triple immunofluorescence staining with anti-CAXII (green), anti-WGA (red, detecting the cell membrane) and anti-calnexin (blue, detecting the ER compartment) are reported. Scale bars = 50 μm and = 5 μm for the lower and higher magnification respectively. The cell viability of the HCC cell lines treated with different doses of S4 (µM) (E) and compound 25 (µM) (F) under normoxia (N = 21% O 2 , black triangles) or hypoxia (H = 1% O 2 , white triangles) for 72 h was evaluated using the MTT assay. The data show the percentage of viable cells of the untreated control and represent the mean of six replicate reactions from 3 independent experiments. IC 50 values for S4 were >100 μM for all HCC cell lines grown under normoxic conditions and 57.4, 53.9 and >100 μM for C3 A, PLC/PRF/5 and SNU-449 exposed to hypoxia respectively. For compound 25, C3 A, PLC/PRF/5 and SNU-449 cells grown under normoxia displayed IC 50 values of 198.5, 142.9 and >200 μM respectively. All the HCC cell lines exposed to hypoxia displayed IC 50 values >200 μM for compound 25.

    Techniques Used: Expressing, Functional Assay, Inhibition, Cell Culture, Western Blot, Flow Cytometry, Confocal Laser Scanning Microscopy, Immunofluorescence, Staining, Membrane, MTT Assay, Control

    Effects of omeprazole on HCC cell line viability and on the tumor microenvironment of HCC tissue explants. (A) The protein expression of a1, C1, β-actin and α-tubulin was assessed by western blotting in cell lysates of the C3A, PLC/PRF/5 and SNU-449 cell lines. (B) The HCC cell lines were treated with different doses of omeprazole, and cell viability was evaluated using the MTT assay. The data on the y-axes report the percentage of viable cells of the untreated control and represent the mean of six replicate reactions from 3 independent experiments. The calculated IC 50 values for omeprazole are 100.9, 39.4, and 128.4 μg/ml for C3A, PLC/PRF/5 and SNU-449 respectively. (C) Expression levels of the indicated genes in HCC tissue explants ( MYC, VIM, CDH1, CCL22, IFNG N = 12; TNF , N = 8) cultured ex vivo in the presence of 100 μg/ml omeprazole or the vehicle of the drug for 24 h. The gene expression data are reported as 2 −ΔCt values. The p-values are calculated by the paired t test comparing cells treated with omeprazole or the vehicle.
    Figure Legend Snippet: Effects of omeprazole on HCC cell line viability and on the tumor microenvironment of HCC tissue explants. (A) The protein expression of a1, C1, β-actin and α-tubulin was assessed by western blotting in cell lysates of the C3A, PLC/PRF/5 and SNU-449 cell lines. (B) The HCC cell lines were treated with different doses of omeprazole, and cell viability was evaluated using the MTT assay. The data on the y-axes report the percentage of viable cells of the untreated control and represent the mean of six replicate reactions from 3 independent experiments. The calculated IC 50 values for omeprazole are 100.9, 39.4, and 128.4 μg/ml for C3A, PLC/PRF/5 and SNU-449 respectively. (C) Expression levels of the indicated genes in HCC tissue explants ( MYC, VIM, CDH1, CCL22, IFNG N = 12; TNF , N = 8) cultured ex vivo in the presence of 100 μg/ml omeprazole or the vehicle of the drug for 24 h. The gene expression data are reported as 2 −ΔCt values. The p-values are calculated by the paired t test comparing cells treated with omeprazole or the vehicle.

    Techniques Used: Expressing, Western Blot, MTT Assay, Control, Cell Culture, Ex Vivo, Gene Expression

    Related Articles

    other:

    Article Title: In Vitro Antidiabetic Activity and Mechanism of Action of Methanolic Extract of Opuntia stricta Cladodes
    Article Snippet: The INS‐1 cells ( Rattus norvegicus , male, pancreatic β ‐cell; AddexBio, RRID:CVCL_0351), Caco‐2 cells ( Homo sapiens , male, colon epithelium; American Type Culture Collection [ATCC] HTB‐37, RRID:CVCL_0025), and L6 myoblasts ( Rattus norvegicus , male, skeletal muscle myoblast; RIKEN Cell Bank, RRID:CVCL_0385) were procured from Highveld Biological, South Africa, while the C3A subclone of HepG2 cells ( Homo sapiens , female, hepatocytes, liver tissue; ATCC CRL‐10741, RRID:CVCL_1848) was sourced from the ATCC (Manassas, Virginia, United States).

    Article Title: Discovery of Sulfonamide Pantothenate Kinase Activators and Elucidation of the Role of Isoform Selectivity in Cellular Pantothenate Kinase Activation.
    Article Snippet: Human C3A obtained from ATCC were maintained in Eagle’s minimum Essential medium (ATCC) supplemented with 2 mM glutamine, 10% fetal bovine serum, 50 U/ml penicillin, and 50 mg/ mL streptomycin.

    Article Title: Discovery of Sulfonamide Pantothenate Kinase Activators and Elucidation of the Role of Isoform Selectivity in Cellular Pantothenate Kinase Activation
    Article Snippet: Human C3A obtained from ATCC were maintained in Eagle’s minimum Essential medium (ATCC) supplemented with 2 mM glutamine, 10% fetal bovine serum, 50 U/ml penicillin, and 50 mg/mL streptomycin.

    Cell Culture:

    Article Title: Development of a Lipidomics-Based Cell Screening Platform for Indirect Antioxidants Targeting Oxidized Lipid Droplet Formation and Mitochondrial Membrane Abnormality.
    Article Snippet: Dulbecco’s PBS (D-PBS; FUJIFILM Wako Pure Chemical Industries Ltd., Osaka, Japan) was added to the sample to restore the original protein concentration, and the sample was centrifuged using a tube equipped with a 0.22 μm membrane filter (Merck Millipore Ltd.). .. A human liver-derived cell line, C3A (CRL-10741, American Type Culture Collection, Manassas, VA, USA) was used for cell culture experiments at passages 21 to 23. ..

    Virus:

    Article Title: The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-ORF2 Rainer Ulrich, Friedrich Loeffler Institute (FLI), Greifswald N/A Anti-β-actin Sigma-Aldrich Cat# A2228; RRID: AB_476697 Anti-HA Cell Signaling Technology Cat# 3724; RRID: AB_1549585 Anti-V5 Cell Signaling Technology Cat# 13202; RRID: AB_2687461 Anti-MAVS Cell Signaling Technology Cat# 3993; RRID: AB_823565 Anti-pTBK1 Cell Signaling Technology Cat# 5483; RRID: AB_10693472 Anti-IRF3 Cell Signaling Technology Cat# 11904; RRID: AB_2722521 Anti-pIRF3 Cell Signaling Technology Cat# 4947; RRID: AB_823547 Bacterial and virus strains HEV-3 Kernow-C1/p6 strain Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A HEV-3 Kernow-C1/p6 strain ORF2:GFP11 Hu et al.48 N/A Stbl2 competent bacteria Thermo Fisher Cat# 10268019 Escherichia coli BL21 (DE3) Arie Geerlof, Helmholtz Munich, Munich N/A Biological samples Human tissue section of patient with cardiac amyloidosis Carolin Mogler, Institute of Pathology, Technical University of Munich N/A Non-infected pig liver tissue Tian et al.50 N/A HEV-3 US-2 infected pig liver tissue Tian et al.50 N/A Chemicals, peptides, and recombinant proteins TBK1 inhibitor InvivoGen Cat# tlrl-bx7 Thioflavin S (ThS) Sigma-Aldrich Cat# T1892 poly(I:C) High Molecular Weight (HMW) InvivoGen Cat# tlrl-pic TransIT-LT1 transfection reagent Merck Cat# MIR2304 Critical commercial assays mMESSAGE mMACHINE T7 kit Invitrogen Cat# AM1344 Experimental models: Cell lines HepG2/C3A ATCC Cat# CRL-3581; RRID: CVCL_1098 HepG2/C3A ectopically expressing ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing ΔN-ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing GFP1-10 Hu et al.48 N/A S10-3 Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A Caco-2 ATCC Cat# HTB-37; RRID: CVCL_0025 HuH7.5 Charles Rice, The Rockefeller University, New York City N/A (Continued on next page) 18 Cell Reports 45, 117513, June 23, 2026 .. The human cell lines HepG2/C3A (ATCC CRL-3581; human, male), S10-3 (a kind gift from Suzanne Emerson, NIH; human male), Caco-2 (ATCC HTB-37; human, male), HuH7.5 (a kind gift from Charles Rice, The Rockefeller University; human male) and HEK293T (ATCC CRL-3216; human, female) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, high glucose, GlutaMAX supplement) with 10% fetal bovine serum (FBS, Capricorn) and 1% penicillin/streptomycin (Gibco), referred to as complete DMEM (cDMEM).

    Bacteria:

    Article Title: The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-ORF2 Rainer Ulrich, Friedrich Loeffler Institute (FLI), Greifswald N/A Anti-β-actin Sigma-Aldrich Cat# A2228; RRID: AB_476697 Anti-HA Cell Signaling Technology Cat# 3724; RRID: AB_1549585 Anti-V5 Cell Signaling Technology Cat# 13202; RRID: AB_2687461 Anti-MAVS Cell Signaling Technology Cat# 3993; RRID: AB_823565 Anti-pTBK1 Cell Signaling Technology Cat# 5483; RRID: AB_10693472 Anti-IRF3 Cell Signaling Technology Cat# 11904; RRID: AB_2722521 Anti-pIRF3 Cell Signaling Technology Cat# 4947; RRID: AB_823547 Bacterial and virus strains HEV-3 Kernow-C1/p6 strain Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A HEV-3 Kernow-C1/p6 strain ORF2:GFP11 Hu et al.48 N/A Stbl2 competent bacteria Thermo Fisher Cat# 10268019 Escherichia coli BL21 (DE3) Arie Geerlof, Helmholtz Munich, Munich N/A Biological samples Human tissue section of patient with cardiac amyloidosis Carolin Mogler, Institute of Pathology, Technical University of Munich N/A Non-infected pig liver tissue Tian et al.50 N/A HEV-3 US-2 infected pig liver tissue Tian et al.50 N/A Chemicals, peptides, and recombinant proteins TBK1 inhibitor InvivoGen Cat# tlrl-bx7 Thioflavin S (ThS) Sigma-Aldrich Cat# T1892 poly(I:C) High Molecular Weight (HMW) InvivoGen Cat# tlrl-pic TransIT-LT1 transfection reagent Merck Cat# MIR2304 Critical commercial assays mMESSAGE mMACHINE T7 kit Invitrogen Cat# AM1344 Experimental models: Cell lines HepG2/C3A ATCC Cat# CRL-3581; RRID: CVCL_1098 HepG2/C3A ectopically expressing ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing ΔN-ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing GFP1-10 Hu et al.48 N/A S10-3 Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A Caco-2 ATCC Cat# HTB-37; RRID: CVCL_0025 HuH7.5 Charles Rice, The Rockefeller University, New York City N/A (Continued on next page) 18 Cell Reports 45, 117513, June 23, 2026 .. The human cell lines HepG2/C3A (ATCC CRL-3581; human, male), S10-3 (a kind gift from Suzanne Emerson, NIH; human male), Caco-2 (ATCC HTB-37; human, male), HuH7.5 (a kind gift from Charles Rice, The Rockefeller University; human male) and HEK293T (ATCC CRL-3216; human, female) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, high glucose, GlutaMAX supplement) with 10% fetal bovine serum (FBS, Capricorn) and 1% penicillin/streptomycin (Gibco), referred to as complete DMEM (cDMEM).

    Infection:

    Article Title: The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-ORF2 Rainer Ulrich, Friedrich Loeffler Institute (FLI), Greifswald N/A Anti-β-actin Sigma-Aldrich Cat# A2228; RRID: AB_476697 Anti-HA Cell Signaling Technology Cat# 3724; RRID: AB_1549585 Anti-V5 Cell Signaling Technology Cat# 13202; RRID: AB_2687461 Anti-MAVS Cell Signaling Technology Cat# 3993; RRID: AB_823565 Anti-pTBK1 Cell Signaling Technology Cat# 5483; RRID: AB_10693472 Anti-IRF3 Cell Signaling Technology Cat# 11904; RRID: AB_2722521 Anti-pIRF3 Cell Signaling Technology Cat# 4947; RRID: AB_823547 Bacterial and virus strains HEV-3 Kernow-C1/p6 strain Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A HEV-3 Kernow-C1/p6 strain ORF2:GFP11 Hu et al.48 N/A Stbl2 competent bacteria Thermo Fisher Cat# 10268019 Escherichia coli BL21 (DE3) Arie Geerlof, Helmholtz Munich, Munich N/A Biological samples Human tissue section of patient with cardiac amyloidosis Carolin Mogler, Institute of Pathology, Technical University of Munich N/A Non-infected pig liver tissue Tian et al.50 N/A HEV-3 US-2 infected pig liver tissue Tian et al.50 N/A Chemicals, peptides, and recombinant proteins TBK1 inhibitor InvivoGen Cat# tlrl-bx7 Thioflavin S (ThS) Sigma-Aldrich Cat# T1892 poly(I:C) High Molecular Weight (HMW) InvivoGen Cat# tlrl-pic TransIT-LT1 transfection reagent Merck Cat# MIR2304 Critical commercial assays mMESSAGE mMACHINE T7 kit Invitrogen Cat# AM1344 Experimental models: Cell lines HepG2/C3A ATCC Cat# CRL-3581; RRID: CVCL_1098 HepG2/C3A ectopically expressing ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing ΔN-ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing GFP1-10 Hu et al.48 N/A S10-3 Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A Caco-2 ATCC Cat# HTB-37; RRID: CVCL_0025 HuH7.5 Charles Rice, The Rockefeller University, New York City N/A (Continued on next page) 18 Cell Reports 45, 117513, June 23, 2026 .. The human cell lines HepG2/C3A (ATCC CRL-3581; human, male), S10-3 (a kind gift from Suzanne Emerson, NIH; human male), Caco-2 (ATCC HTB-37; human, male), HuH7.5 (a kind gift from Charles Rice, The Rockefeller University; human male) and HEK293T (ATCC CRL-3216; human, female) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, high glucose, GlutaMAX supplement) with 10% fetal bovine serum (FBS, Capricorn) and 1% penicillin/streptomycin (Gibco), referred to as complete DMEM (cDMEM).

    Recombinant:

    Article Title: The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-ORF2 Rainer Ulrich, Friedrich Loeffler Institute (FLI), Greifswald N/A Anti-β-actin Sigma-Aldrich Cat# A2228; RRID: AB_476697 Anti-HA Cell Signaling Technology Cat# 3724; RRID: AB_1549585 Anti-V5 Cell Signaling Technology Cat# 13202; RRID: AB_2687461 Anti-MAVS Cell Signaling Technology Cat# 3993; RRID: AB_823565 Anti-pTBK1 Cell Signaling Technology Cat# 5483; RRID: AB_10693472 Anti-IRF3 Cell Signaling Technology Cat# 11904; RRID: AB_2722521 Anti-pIRF3 Cell Signaling Technology Cat# 4947; RRID: AB_823547 Bacterial and virus strains HEV-3 Kernow-C1/p6 strain Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A HEV-3 Kernow-C1/p6 strain ORF2:GFP11 Hu et al.48 N/A Stbl2 competent bacteria Thermo Fisher Cat# 10268019 Escherichia coli BL21 (DE3) Arie Geerlof, Helmholtz Munich, Munich N/A Biological samples Human tissue section of patient with cardiac amyloidosis Carolin Mogler, Institute of Pathology, Technical University of Munich N/A Non-infected pig liver tissue Tian et al.50 N/A HEV-3 US-2 infected pig liver tissue Tian et al.50 N/A Chemicals, peptides, and recombinant proteins TBK1 inhibitor InvivoGen Cat# tlrl-bx7 Thioflavin S (ThS) Sigma-Aldrich Cat# T1892 poly(I:C) High Molecular Weight (HMW) InvivoGen Cat# tlrl-pic TransIT-LT1 transfection reagent Merck Cat# MIR2304 Critical commercial assays mMESSAGE mMACHINE T7 kit Invitrogen Cat# AM1344 Experimental models: Cell lines HepG2/C3A ATCC Cat# CRL-3581; RRID: CVCL_1098 HepG2/C3A ectopically expressing ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing ΔN-ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing GFP1-10 Hu et al.48 N/A S10-3 Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A Caco-2 ATCC Cat# HTB-37; RRID: CVCL_0025 HuH7.5 Charles Rice, The Rockefeller University, New York City N/A (Continued on next page) 18 Cell Reports 45, 117513, June 23, 2026 .. The human cell lines HepG2/C3A (ATCC CRL-3581; human, male), S10-3 (a kind gift from Suzanne Emerson, NIH; human male), Caco-2 (ATCC HTB-37; human, male), HuH7.5 (a kind gift from Charles Rice, The Rockefeller University; human male) and HEK293T (ATCC CRL-3216; human, female) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, high glucose, GlutaMAX supplement) with 10% fetal bovine serum (FBS, Capricorn) and 1% penicillin/streptomycin (Gibco), referred to as complete DMEM (cDMEM).

    High Molecular Weight:

    Article Title: The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-ORF2 Rainer Ulrich, Friedrich Loeffler Institute (FLI), Greifswald N/A Anti-β-actin Sigma-Aldrich Cat# A2228; RRID: AB_476697 Anti-HA Cell Signaling Technology Cat# 3724; RRID: AB_1549585 Anti-V5 Cell Signaling Technology Cat# 13202; RRID: AB_2687461 Anti-MAVS Cell Signaling Technology Cat# 3993; RRID: AB_823565 Anti-pTBK1 Cell Signaling Technology Cat# 5483; RRID: AB_10693472 Anti-IRF3 Cell Signaling Technology Cat# 11904; RRID: AB_2722521 Anti-pIRF3 Cell Signaling Technology Cat# 4947; RRID: AB_823547 Bacterial and virus strains HEV-3 Kernow-C1/p6 strain Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A HEV-3 Kernow-C1/p6 strain ORF2:GFP11 Hu et al.48 N/A Stbl2 competent bacteria Thermo Fisher Cat# 10268019 Escherichia coli BL21 (DE3) Arie Geerlof, Helmholtz Munich, Munich N/A Biological samples Human tissue section of patient with cardiac amyloidosis Carolin Mogler, Institute of Pathology, Technical University of Munich N/A Non-infected pig liver tissue Tian et al.50 N/A HEV-3 US-2 infected pig liver tissue Tian et al.50 N/A Chemicals, peptides, and recombinant proteins TBK1 inhibitor InvivoGen Cat# tlrl-bx7 Thioflavin S (ThS) Sigma-Aldrich Cat# T1892 poly(I:C) High Molecular Weight (HMW) InvivoGen Cat# tlrl-pic TransIT-LT1 transfection reagent Merck Cat# MIR2304 Critical commercial assays mMESSAGE mMACHINE T7 kit Invitrogen Cat# AM1344 Experimental models: Cell lines HepG2/C3A ATCC Cat# CRL-3581; RRID: CVCL_1098 HepG2/C3A ectopically expressing ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing ΔN-ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing GFP1-10 Hu et al.48 N/A S10-3 Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A Caco-2 ATCC Cat# HTB-37; RRID: CVCL_0025 HuH7.5 Charles Rice, The Rockefeller University, New York City N/A (Continued on next page) 18 Cell Reports 45, 117513, June 23, 2026 .. The human cell lines HepG2/C3A (ATCC CRL-3581; human, male), S10-3 (a kind gift from Suzanne Emerson, NIH; human male), Caco-2 (ATCC HTB-37; human, male), HuH7.5 (a kind gift from Charles Rice, The Rockefeller University; human male) and HEK293T (ATCC CRL-3216; human, female) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, high glucose, GlutaMAX supplement) with 10% fetal bovine serum (FBS, Capricorn) and 1% penicillin/streptomycin (Gibco), referred to as complete DMEM (cDMEM).

    Transfection:

    Article Title: The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-ORF2 Rainer Ulrich, Friedrich Loeffler Institute (FLI), Greifswald N/A Anti-β-actin Sigma-Aldrich Cat# A2228; RRID: AB_476697 Anti-HA Cell Signaling Technology Cat# 3724; RRID: AB_1549585 Anti-V5 Cell Signaling Technology Cat# 13202; RRID: AB_2687461 Anti-MAVS Cell Signaling Technology Cat# 3993; RRID: AB_823565 Anti-pTBK1 Cell Signaling Technology Cat# 5483; RRID: AB_10693472 Anti-IRF3 Cell Signaling Technology Cat# 11904; RRID: AB_2722521 Anti-pIRF3 Cell Signaling Technology Cat# 4947; RRID: AB_823547 Bacterial and virus strains HEV-3 Kernow-C1/p6 strain Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A HEV-3 Kernow-C1/p6 strain ORF2:GFP11 Hu et al.48 N/A Stbl2 competent bacteria Thermo Fisher Cat# 10268019 Escherichia coli BL21 (DE3) Arie Geerlof, Helmholtz Munich, Munich N/A Biological samples Human tissue section of patient with cardiac amyloidosis Carolin Mogler, Institute of Pathology, Technical University of Munich N/A Non-infected pig liver tissue Tian et al.50 N/A HEV-3 US-2 infected pig liver tissue Tian et al.50 N/A Chemicals, peptides, and recombinant proteins TBK1 inhibitor InvivoGen Cat# tlrl-bx7 Thioflavin S (ThS) Sigma-Aldrich Cat# T1892 poly(I:C) High Molecular Weight (HMW) InvivoGen Cat# tlrl-pic TransIT-LT1 transfection reagent Merck Cat# MIR2304 Critical commercial assays mMESSAGE mMACHINE T7 kit Invitrogen Cat# AM1344 Experimental models: Cell lines HepG2/C3A ATCC Cat# CRL-3581; RRID: CVCL_1098 HepG2/C3A ectopically expressing ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing ΔN-ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing GFP1-10 Hu et al.48 N/A S10-3 Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A Caco-2 ATCC Cat# HTB-37; RRID: CVCL_0025 HuH7.5 Charles Rice, The Rockefeller University, New York City N/A (Continued on next page) 18 Cell Reports 45, 117513, June 23, 2026 .. The human cell lines HepG2/C3A (ATCC CRL-3581; human, male), S10-3 (a kind gift from Suzanne Emerson, NIH; human male), Caco-2 (ATCC HTB-37; human, male), HuH7.5 (a kind gift from Charles Rice, The Rockefeller University; human male) and HEK293T (ATCC CRL-3216; human, female) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, high glucose, GlutaMAX supplement) with 10% fetal bovine serum (FBS, Capricorn) and 1% penicillin/streptomycin (Gibco), referred to as complete DMEM (cDMEM).

    Expressing:

    Article Title: The hepatitis E virus capsid protein forms amyloid-like fibrils that sequester TANK-binding kinase 1 to dampen antiviral responses.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-ORF2 Rainer Ulrich, Friedrich Loeffler Institute (FLI), Greifswald N/A Anti-β-actin Sigma-Aldrich Cat# A2228; RRID: AB_476697 Anti-HA Cell Signaling Technology Cat# 3724; RRID: AB_1549585 Anti-V5 Cell Signaling Technology Cat# 13202; RRID: AB_2687461 Anti-MAVS Cell Signaling Technology Cat# 3993; RRID: AB_823565 Anti-pTBK1 Cell Signaling Technology Cat# 5483; RRID: AB_10693472 Anti-IRF3 Cell Signaling Technology Cat# 11904; RRID: AB_2722521 Anti-pIRF3 Cell Signaling Technology Cat# 4947; RRID: AB_823547 Bacterial and virus strains HEV-3 Kernow-C1/p6 strain Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A HEV-3 Kernow-C1/p6 strain ORF2:GFP11 Hu et al.48 N/A Stbl2 competent bacteria Thermo Fisher Cat# 10268019 Escherichia coli BL21 (DE3) Arie Geerlof, Helmholtz Munich, Munich N/A Biological samples Human tissue section of patient with cardiac amyloidosis Carolin Mogler, Institute of Pathology, Technical University of Munich N/A Non-infected pig liver tissue Tian et al.50 N/A HEV-3 US-2 infected pig liver tissue Tian et al.50 N/A Chemicals, peptides, and recombinant proteins TBK1 inhibitor InvivoGen Cat# tlrl-bx7 Thioflavin S (ThS) Sigma-Aldrich Cat# T1892 poly(I:C) High Molecular Weight (HMW) InvivoGen Cat# tlrl-pic TransIT-LT1 transfection reagent Merck Cat# MIR2304 Critical commercial assays mMESSAGE mMACHINE T7 kit Invitrogen Cat# AM1344 Experimental models: Cell lines HepG2/C3A ATCC Cat# CRL-3581; RRID: CVCL_1098 HepG2/C3A ectopically expressing ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing ΔN-ORF2 (HEV-3 Kernow-C1/p6 strain) This study N/A HepG2/C3A ectopically expressing GFP1-10 Hu et al.48 N/A S10-3 Suzanne Emerson, Nationale Institutes of Health (NIH), Bethesda, Maryland N/A Caco-2 ATCC Cat# HTB-37; RRID: CVCL_0025 HuH7.5 Charles Rice, The Rockefeller University, New York City N/A (Continued on next page) 18 Cell Reports 45, 117513, June 23, 2026 .. The human cell lines HepG2/C3A (ATCC CRL-3581; human, male), S10-3 (a kind gift from Suzanne Emerson, NIH; human male), Caco-2 (ATCC HTB-37; human, male), HuH7.5 (a kind gift from Charles Rice, The Rockefeller University; human male) and HEK293T (ATCC CRL-3216; human, female) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, high glucose, GlutaMAX supplement) with 10% fetal bovine serum (FBS, Capricorn) and 1% penicillin/streptomycin (Gibco), referred to as complete DMEM (cDMEM).

    Protease Inhibitor:

    Article Title: Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity.
    Article Snippet: .. HepG2 (ATCC, CRL-3581) were grown in RPMI-1640 and DMEM Glutamax with 10% FBS (Thermo Fisher, 10270-106) for 24 h. The cells were then washed with PBS and harvested with RIPA containing protease inhibitor. ..



    Similar Products

    90
    Carl Zeiss line-scan fluorescence intensity profile function
    Line Scan Fluorescence Intensity Profile Function, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/line-scan+function+in/line+ophthalmoscope+scan/pm40664038-328-26-35
    Average 90 stars, based on 1 article reviews
    line-scan fluorescence intensity profile function - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    MetaMorph Inc line-scan function in
    Line Scan Function In, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/line-scan+function+in/linescan+function/pm39271061-367-22-25
    Average 90 stars, based on 1 article reviews
    line-scan function in - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Carl Zeiss high-speed line-scan function
    a Structural model of <t>NOPLight</t> and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).
    High Speed Line Scan Function, supplied by Carl Zeiss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/line-scan+function+in/axiocom+camera+hsm/pmc11199706-312-7-20
    Average 90 stars, based on 1 article reviews
    high-speed line-scan function - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    MetaMorph Inc line scan function
    a Structural model of <t>NOPLight</t> and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).
    Line Scan Function, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/line-scan+function+in/linescan+function/pm36077281-480-32-38
    Average 90 stars, based on 1 article reviews
    line scan function - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    MetaMorph Inc line scan function in
    a Structural model of <t>NOPLight</t> and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).
    Line Scan Function In, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/line-scan+function+in/linescan+function/pm35041746-244-15-19
    Average 90 stars, based on 1 article reviews
    line scan function in - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    MetaMorph Inc line scan function in metamorph software
    a Structural model of <t>NOPLight</t> and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).
    Line Scan Function In Metamorph Software, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/line-scan+function+in/linescan+module+of+metamorph+software/pmc07776996__pnas__2011870117__sapp-91-4-10
    Average 90 stars, based on 1 article reviews
    line scan function in metamorph software - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    MetaMorph Inc line scan function of
    a Structural model of <t>NOPLight</t> and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).
    Line Scan Function Of, supplied by MetaMorph Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/line-scan+function+in/linescan+function/pmc07272295-253-1-5
    Average 90 stars, based on 1 article reviews
    line scan function of - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    a Structural model of NOPLight and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).

    Journal: Nature Communications

    Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

    doi: 10.1038/s41467-024-49712-0

    Figure Lengend Snippet: a Structural model of NOPLight and screening summary. n ≥ 3 cells for each variant. b Representative images of HEK293T cells (top; scale bars, 10 µm) and neurons (bottom; scale bars, 20 µm) expressing NOPLight before and after application of 1 µM N/OFQ and ΔF heat map. c Responses of NOPLight or NOPLight-ctr in HEK293T cell and neurons to 1 µM N/OFQ, followed by competition with 10 µM J-113397. d Quantification of maximal responses from ( c ), n = 38, 30, 22, 27 cells from three independent experiments, respectively. Data shown as mean ± SD. (One-sided Mann–Whitney U -test, **** P < 0.0001, P = 1.003 × 10 −12 , and 1.262 × 10 −9 for NOPLight versus NOPLight-ctr in HEK293T and neurons). e Normalized response of HEK293T cells and neurons expressing NOPLight to N/OFQ titrations (mean ± SD) fitted with three-parameter Hill equation. n = 3 independent experiments per concentration. f Line-scan time plot of NOPLight ΔF/F 0 (gray) from membrane-pixels shown in bottom. Right, quantification of time constant (τ) from four independent experiments. Data represented as mean ± SD. g Left: experimental schematics and images (scale bars, 20 µm), right: time plot of normalized ΔF/F 0 from a representative experiment (gray) with quantified time constant (τ off ). Data represented as mean ± SD. h Maximal NOPLight response to: NCS, Nocistatin; J11, J-113397; UFP, UFP-101; RO, Ro 64-6198; MCO, MCOPPB; OFQ1-11, Orphanin-FQ (1–11)). * P < 0.05, ** P < 0.01, P = 0.024, Nocistatin; 0.0012, J-113397; 0.0012, UFP-101. n = 9 cells except MCO ( n = 8) from three independent experiments. i Maximal NOPLight response to endogenous opioid ligands (1 µM). ** P < 0.01, P = 0.003, Dynorphin A; P = 0.003, Dynorphin-B; P = 0.003, Leu-Enkephalin; P = 0.003, Met-Enkephalin; P = 0.003, β-endorphin. n = 9 from three independent experiments. Statistical comparisons in ( h , i ) by one-sided pairwise Mann–Whitney rank test with post hoc Bonferroni correction, data represented as mean ± SEM. j NOPLight response to neurotransmitters (DA dopamine, ACh acetylcholine, GABA gamma-Aminobutyric, all 1 mM). n = 29 (DA) or 30 (ACh, GABA) cells from three independent experiments (two-sided paired t -test, **** P < 0.0001, P = 2.45 × 10 −22 , 7.46 × 10 −19 , and 7.82 × 10 −21 , respectively).

    Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

    Techniques: Variant Assay, Expressing, MANN-WHITNEY, Concentration Assay, Membrane

    a Expression of NOPLight in the ARC. Scale bar, 200 µm. Insets, scale bars, 50 µm. b – f Change in NOPLight fluorescence measured in ARC neurons in response to bath-applied N/OFQ or release of chemogenetically-activated PNOC neurons. Fluorescence was detected from 0.15–0.2 mm 2 ROIs. Each experiment was performed in a different brain slice. b NOPLight responses of a single ROI to increasing N/OFQ concentrations. c Concentration-response relation showing N/OFQ effect on the fluorescence of NOPLight (black) and NOPLight-Ctr (gray) -expressing cells in the ARC. Data represented as mean ± SEM. Inset, mean fluorescence increases in response to different concentrations of N/OFQ. Color-code as in ( b ). d Experimental schematic for chemogenetic experiments in brain slices. e Representative immunohistochemical image showing DREADD (hM3Dq) expression in PNOC neurons of the ARC as well as pan-neuronal expression of NOPLight. Scale bar, 100 µm. Magnification is shown on the right. Scale bar, 20 µm. f Perforated patch-clamp recordings from a hM3Dq-expressing PNOC neuron showing the effect of 10 min CNO application (3 µM) on action potential frequency. Left, rate histogram (bin width 60 s). Right, representative sections of the original recording correspond to the times indicated by the blue and red color codes. g – i Changes (mean ± SEM) in NOPLight fluorescence measured in the ARC in response to activation of hM3Dq-expressing PNOC neurons by 10 min bath application of 3 µM clozapine-N-oxide (CNO) ( g ) and 100 nM and 500 nM N/OFQ ( h ). g Upper and lower are the same data: traces in the upper panel are aligned to the CNO application, and traces in the lower panel are aligned to the response onset. Recordings in ( g , h ) were performed from the same brain slices. Bars indicate the application of CNO and N/OFQ, respectively. Scale bars apply to ( g , h ). i Maximal fluorescence changes upon applications of CNO and N/OFQ, respectively. The box represents the interquartile range, indicating the 25th and 75th percentiles with a median marked by a horizontal line inside the box. Whiskers extend to the minimum and maximum values, excluding outliers (•). The numbers in brackets represent the number of experiments (brain slices). N values indicate the number of animals. Data represented as mean ± SEM.

    Journal: Nature Communications

    Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

    doi: 10.1038/s41467-024-49712-0

    Figure Lengend Snippet: a Expression of NOPLight in the ARC. Scale bar, 200 µm. Insets, scale bars, 50 µm. b – f Change in NOPLight fluorescence measured in ARC neurons in response to bath-applied N/OFQ or release of chemogenetically-activated PNOC neurons. Fluorescence was detected from 0.15–0.2 mm 2 ROIs. Each experiment was performed in a different brain slice. b NOPLight responses of a single ROI to increasing N/OFQ concentrations. c Concentration-response relation showing N/OFQ effect on the fluorescence of NOPLight (black) and NOPLight-Ctr (gray) -expressing cells in the ARC. Data represented as mean ± SEM. Inset, mean fluorescence increases in response to different concentrations of N/OFQ. Color-code as in ( b ). d Experimental schematic for chemogenetic experiments in brain slices. e Representative immunohistochemical image showing DREADD (hM3Dq) expression in PNOC neurons of the ARC as well as pan-neuronal expression of NOPLight. Scale bar, 100 µm. Magnification is shown on the right. Scale bar, 20 µm. f Perforated patch-clamp recordings from a hM3Dq-expressing PNOC neuron showing the effect of 10 min CNO application (3 µM) on action potential frequency. Left, rate histogram (bin width 60 s). Right, representative sections of the original recording correspond to the times indicated by the blue and red color codes. g – i Changes (mean ± SEM) in NOPLight fluorescence measured in the ARC in response to activation of hM3Dq-expressing PNOC neurons by 10 min bath application of 3 µM clozapine-N-oxide (CNO) ( g ) and 100 nM and 500 nM N/OFQ ( h ). g Upper and lower are the same data: traces in the upper panel are aligned to the CNO application, and traces in the lower panel are aligned to the response onset. Recordings in ( g , h ) were performed from the same brain slices. Bars indicate the application of CNO and N/OFQ, respectively. Scale bars apply to ( g , h ). i Maximal fluorescence changes upon applications of CNO and N/OFQ, respectively. The box represents the interquartile range, indicating the 25th and 75th percentiles with a median marked by a horizontal line inside the box. Whiskers extend to the minimum and maximum values, excluding outliers (•). The numbers in brackets represent the number of experiments (brain slices). N values indicate the number of animals. Data represented as mean ± SEM.

    Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

    Techniques: Expressing, Fluorescence, Slice Preparation, Concentration Assay, Immunohistochemical staining, Patch Clamp, Activation Assay

    a Fiber photometry schematic. Cartoon of NOPLight viral injection and fiber implant in the VTA. b Representative image showing DAPI (blue) and NOPLight (green) expression with fiber placement. c Left: Averaged traces of NOPLight fluorescence after systemic (i.p.) injection of vehicle (veh, black; n = 11 mice) or 1, 5, or 10 mg/kg of selective NOPR agonist Ro 64-6198 (RO, green; n = 5, 12, or 16 mice/group, respectively). Right: Mean NOPLight fluorescence 20–25 min after RO injection increases dose-dependently (two-tailed Mann–Whitney test, ** p = 0.0012, **** p < 0.0001). Data represented as mean ± SEM. d Left: Averaged traces of NOPLight fluorescence after 10 mg/kg RO (pink), 10 mg/kg selective NOPR antagonist LY2940094 (LY, o.g., blue), or both (purple) ( n = 4 mice). Right: Increase in signal 20–25 min after RO is blocked by LY pretreatment (two-tailed Mann–Whitney test, * p = 0.0286, # p = 0.0286, n = 4 mice). Data represented as mean ± SEM. e Same as ( d ) for NOPR antagonist J-113397 (J11, i.p.) (two-tailed Mann–Whitney test, ## p = 0.0028, #### p < 0.0001, **** p < 0.0001, n = 9 mice, RO; 4 mice, J11; 9 mice, J11 + RO). Data represented as mean ± SEM. f Top: Cartoon of FLEX-NOPLight or NOPLight-ctr viral injection and fiber implant in the VTA. Bottom: Representative image showing expression of DAPI (blue) and FLEX-NOPLight (left, green) or NOPLight-ctr (right, green), with fiber placement in VTA. g Averaged traces of NOPLight (green), FLEX-NOPLight (blue), or NOPLight-ctr (gray) fluorescence ( n = 16, 3, 6 mice, respectively) after systemic (i.p.) injection of 10 mg/kg RO. Data represented as mean ± SEM. h Area under the curve (AUC) of each NOPLight variant after RO injection (two-tailed Mann–Whitney test, * p = 0.0275, *** p = 0.0001, **** p < 0.0001, ns not significant ( p = 0.9577), # p = 0.0238, #### p < 0.0001. Group sizes left to right: n = 11, 5, 12, 16, 3, and 6 mice). Data represented as mean ± SEM. PN paranigral VTA, veh vehicle, BL baseline.

    Journal: Nature Communications

    Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

    doi: 10.1038/s41467-024-49712-0

    Figure Lengend Snippet: a Fiber photometry schematic. Cartoon of NOPLight viral injection and fiber implant in the VTA. b Representative image showing DAPI (blue) and NOPLight (green) expression with fiber placement. c Left: Averaged traces of NOPLight fluorescence after systemic (i.p.) injection of vehicle (veh, black; n = 11 mice) or 1, 5, or 10 mg/kg of selective NOPR agonist Ro 64-6198 (RO, green; n = 5, 12, or 16 mice/group, respectively). Right: Mean NOPLight fluorescence 20–25 min after RO injection increases dose-dependently (two-tailed Mann–Whitney test, ** p = 0.0012, **** p < 0.0001). Data represented as mean ± SEM. d Left: Averaged traces of NOPLight fluorescence after 10 mg/kg RO (pink), 10 mg/kg selective NOPR antagonist LY2940094 (LY, o.g., blue), or both (purple) ( n = 4 mice). Right: Increase in signal 20–25 min after RO is blocked by LY pretreatment (two-tailed Mann–Whitney test, * p = 0.0286, # p = 0.0286, n = 4 mice). Data represented as mean ± SEM. e Same as ( d ) for NOPR antagonist J-113397 (J11, i.p.) (two-tailed Mann–Whitney test, ## p = 0.0028, #### p < 0.0001, **** p < 0.0001, n = 9 mice, RO; 4 mice, J11; 9 mice, J11 + RO). Data represented as mean ± SEM. f Top: Cartoon of FLEX-NOPLight or NOPLight-ctr viral injection and fiber implant in the VTA. Bottom: Representative image showing expression of DAPI (blue) and FLEX-NOPLight (left, green) or NOPLight-ctr (right, green), with fiber placement in VTA. g Averaged traces of NOPLight (green), FLEX-NOPLight (blue), or NOPLight-ctr (gray) fluorescence ( n = 16, 3, 6 mice, respectively) after systemic (i.p.) injection of 10 mg/kg RO. Data represented as mean ± SEM. h Area under the curve (AUC) of each NOPLight variant after RO injection (two-tailed Mann–Whitney test, * p = 0.0275, *** p = 0.0001, **** p < 0.0001, ns not significant ( p = 0.9577), # p = 0.0238, #### p < 0.0001. Group sizes left to right: n = 11, 5, 12, 16, 3, and 6 mice). Data represented as mean ± SEM. PN paranigral VTA, veh vehicle, BL baseline.

    Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

    Techniques: Injection, Expressing, Fluorescence, Two Tailed Test, MANN-WHITNEY, Variant Assay

    a Schematic of fiber photometry setup. Coronal brain cartoon of fiber implant and viral co-injection of FLEX-NOPLight with either DIO-hM3D(Gq) or mCherry in the VTA of PNOC-Cre mice. b Left: Representative traces of FLEX-NOPLight fluorescence after systemic (i.p.) injection of 5 mg/kg clozapine-N-oxide (CNO) in hM3D(Gq) (light green) or mCherry control (dark green) animals. Right: Mean FLEX-NOPLight fluorescence 40–45 min after CNO injection is significantly elevated relative to the pre-injection baseline period (BL) in hM3D(Gq) (two-tailed Wilcoxon test, * p = 0.0391, n = 8 mice) but not control animals (two-tailed Wilcoxon test, p > 0.9999, ns not significant, n = 3 mice). Z-scores for each individual animal averaged at baseline, and 50–55 min are shown (gray lines). Data represented as mean ± SEM. c Left: FLEX-NOPLight fluorescence (green) averaged before injection of 5 mg/kg CNO (0–10 min), and in 5 min bins following injection. 10 mg/kg of selective NOPR antagonist LY2940094 (LY) was administered (o.g.) to the LY + CNO (purple) group 30 min prior to photometry recording (two-way repeated-measures ANOVA with Bonferroni’s post hoc test, * p = 0.0207 (40–45 min), ** p = 0.0094 (45–50 min) or 0.0024 (50–55 min), n = 8 mice, CNO; three mice, LY + CNO). Right: Area under the curve (AUC) of FLEX-NOPLight signal after CNO injection (cumulative, 45 min). Pretreatment with NOPR antagonist LY prevents CNO-induced increases in FLEX-NOPLight fluorescence (two-tailed Mann–Whitney test, # p = 0.0485, n = 8 mice, CNO; three mice, LY + CNO). Data represented as mean ± SEM.

    Journal: Nature Communications

    Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

    doi: 10.1038/s41467-024-49712-0

    Figure Lengend Snippet: a Schematic of fiber photometry setup. Coronal brain cartoon of fiber implant and viral co-injection of FLEX-NOPLight with either DIO-hM3D(Gq) or mCherry in the VTA of PNOC-Cre mice. b Left: Representative traces of FLEX-NOPLight fluorescence after systemic (i.p.) injection of 5 mg/kg clozapine-N-oxide (CNO) in hM3D(Gq) (light green) or mCherry control (dark green) animals. Right: Mean FLEX-NOPLight fluorescence 40–45 min after CNO injection is significantly elevated relative to the pre-injection baseline period (BL) in hM3D(Gq) (two-tailed Wilcoxon test, * p = 0.0391, n = 8 mice) but not control animals (two-tailed Wilcoxon test, p > 0.9999, ns not significant, n = 3 mice). Z-scores for each individual animal averaged at baseline, and 50–55 min are shown (gray lines). Data represented as mean ± SEM. c Left: FLEX-NOPLight fluorescence (green) averaged before injection of 5 mg/kg CNO (0–10 min), and in 5 min bins following injection. 10 mg/kg of selective NOPR antagonist LY2940094 (LY) was administered (o.g.) to the LY + CNO (purple) group 30 min prior to photometry recording (two-way repeated-measures ANOVA with Bonferroni’s post hoc test, * p = 0.0207 (40–45 min), ** p = 0.0094 (45–50 min) or 0.0024 (50–55 min), n = 8 mice, CNO; three mice, LY + CNO). Right: Area under the curve (AUC) of FLEX-NOPLight signal after CNO injection (cumulative, 45 min). Pretreatment with NOPR antagonist LY prevents CNO-induced increases in FLEX-NOPLight fluorescence (two-tailed Mann–Whitney test, # p = 0.0485, n = 8 mice, CNO; three mice, LY + CNO). Data represented as mean ± SEM.

    Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

    Techniques: Injection, Fluorescence, Control, Two Tailed Test, MANN-WHITNEY

    a Fiber photometry schematic. Cartoon of viral injection of NOPLight and fiber implant in VTA of wild-type mice ( n = 7 mice). b Cartoon depicting head-fixed cued-sucrose setup and trial structure. c Averaged traces of NOPLight fluorescence following pretreatment with vehicle (veh, green) or 20 mg/kg NOPR antagonist J-113397 (J11, blue), aligned to tone onset (magenta, shaded). Data represented as mean ± SEM. d Average licks made during vehicle or J-113397 sessions (two-tailed Wilcoxon test, p = 0.1649, ns not significant, n = 7 mice). Data represented as mean ± SEM. e Heat maps of NOPLight fluorescence, rows correspond to trials averaged in ( c ) for vehicle (left) and J11 (right) sessions. f Area under the curve (AUC) for averaged traces from ( c ), calculated over 5-s intervals surrounding cued-sucrose events. Decrease in NOPLight fluorescence during 10% sucrose access (two-tailed Wilcoxon test, ** p = 0.0034, n = 7 mice) is blocked by J11 pretreatment (two-tailed Mann–Whitney test, ## p = 0.0022, n = 7 mice). Data represented as mean ± SEM. g Top: Fiber photometry schematic. Middle: Cartoon depicting fiber implant and viral injection of DIO-GCaMP6m, FLEX-NOPLight, or NOPLight-ctr into the VTA of PNOC-Cre, OPRL1-Cre, or WT mice, respectively. Bottom: Session trial structure. h Left: Averaged trace of pnVTA PNOC GCaMP6m activity during tail lift. Right: AUC for photometry trace calculated over 5-s intervals surrounding tail lift (two-tailed Wilcoxon test, *** p = 0.0002 (5–10 s) or 0.0003 (10–15 s); **** p < 0.0001, n = 4 mice). Data represented as mean ± SEM. i Left: Averaged traces of FLEX-NOPLight (green) and NOPLight-ctr (gray) fluorescence during the tail lift. Right: AUC for photometry traces calculated over 5-s intervals surrounding tail lift. FLEX-NOPLight fluorescence increases during tail lift (two-tailed Wilcoxon test, ** p = 0.0034 (0–5 s) or 0.0093 (5–10 s); n = 3 mice), NOPLight-ctr fluorescence remains unchanged (two-tailed Mann–Whitney test, # p = 0.0264 (0–5 s) or 0.0326 (5–10 s); n = 8 mice, NOPLight-ctr; 3 mice, FLEX-NOPLight). Data represented as mean ± SEM. VITI variable inter-trial interval.

    Journal: Nature Communications

    Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

    doi: 10.1038/s41467-024-49712-0

    Figure Lengend Snippet: a Fiber photometry schematic. Cartoon of viral injection of NOPLight and fiber implant in VTA of wild-type mice ( n = 7 mice). b Cartoon depicting head-fixed cued-sucrose setup and trial structure. c Averaged traces of NOPLight fluorescence following pretreatment with vehicle (veh, green) or 20 mg/kg NOPR antagonist J-113397 (J11, blue), aligned to tone onset (magenta, shaded). Data represented as mean ± SEM. d Average licks made during vehicle or J-113397 sessions (two-tailed Wilcoxon test, p = 0.1649, ns not significant, n = 7 mice). Data represented as mean ± SEM. e Heat maps of NOPLight fluorescence, rows correspond to trials averaged in ( c ) for vehicle (left) and J11 (right) sessions. f Area under the curve (AUC) for averaged traces from ( c ), calculated over 5-s intervals surrounding cued-sucrose events. Decrease in NOPLight fluorescence during 10% sucrose access (two-tailed Wilcoxon test, ** p = 0.0034, n = 7 mice) is blocked by J11 pretreatment (two-tailed Mann–Whitney test, ## p = 0.0022, n = 7 mice). Data represented as mean ± SEM. g Top: Fiber photometry schematic. Middle: Cartoon depicting fiber implant and viral injection of DIO-GCaMP6m, FLEX-NOPLight, or NOPLight-ctr into the VTA of PNOC-Cre, OPRL1-Cre, or WT mice, respectively. Bottom: Session trial structure. h Left: Averaged trace of pnVTA PNOC GCaMP6m activity during tail lift. Right: AUC for photometry trace calculated over 5-s intervals surrounding tail lift (two-tailed Wilcoxon test, *** p = 0.0002 (5–10 s) or 0.0003 (10–15 s); **** p < 0.0001, n = 4 mice). Data represented as mean ± SEM. i Left: Averaged traces of FLEX-NOPLight (green) and NOPLight-ctr (gray) fluorescence during the tail lift. Right: AUC for photometry traces calculated over 5-s intervals surrounding tail lift. FLEX-NOPLight fluorescence increases during tail lift (two-tailed Wilcoxon test, ** p = 0.0034 (0–5 s) or 0.0093 (5–10 s); n = 3 mice), NOPLight-ctr fluorescence remains unchanged (two-tailed Mann–Whitney test, # p = 0.0264 (0–5 s) or 0.0326 (5–10 s); n = 8 mice, NOPLight-ctr; 3 mice, FLEX-NOPLight). Data represented as mean ± SEM. VITI variable inter-trial interval.

    Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

    Techniques: Injection, Fluorescence, Two Tailed Test, MANN-WHITNEY, Activity Assay

    a . Fiber photometry schematic. Cartoon of NOPLight viral injection and fiber implant in the VTA of WT mice ( n = 4 mice). Representative image showing expression of DAPI (blue) and NOPLight (green) with fiber placement in VTA. b . Left: Cartoon depicting operant box setup for the progressive ratio (PR) test. Right: Trial structure for reward delivery during the paradigm. c . Top: Averaged trace of NOPLight signal for all mice ( n = 4), aligned to rewarded active nose pokes (ANPs) made during the PR test. Epoch includes the 5 s light cue (yellow, shaded) that precedes reward delivery. Time to pellet retrieval and duration of consumption period averaged across all trials (brown, shaded). Data represented as mean ± SEM. Bottom: Heat map, each row corresponds to a single, rewarded ANP epoch. d Top: Averaged trace of NOPLight signal for all mice ( n = 4), aligned to non-rewarded ANPs made during the PR test. Data represented as mean ± SEM. Bottom: Heat map, each row corresponds to a single, non-rewarded ANP epoch. e NOPLight fluorescence averaged over 5-s intervals for rewarded (green) and non-rewarded (blue) ANP epochs. Time to pellet retrieval and duration of consumption period averaged across all rewarded trials (brown, shaded). Across rewarded ANP trials, NOPLight signal decreases during reward consumption then immediately increases post-consumption relative to NOPLight signal measured during non-rewarded ANP epochs (two-way repeated-measures ANOVA with Bonferroni’s post hoc test, * p = 0.0122, ** p = 0.0033, *** p = 0.0003, n = 4 mice). Data represented as mean ± SEM. f , g Area under the curve (AUC) for photometry traces from c and d , respectively, calculated over 5-s intervals surrounding ( f ) rewarded ANPs (two-tailed Wilcoxon test, * p = 0.0125 (25–30 s) or 0.031 (30–35 s); ** p = 0.007 (5–10 s) or 0.0042 (15–20 s); *** p = 0.0008 (10–15 s); n = 4 mice) and ( g ) non-rewarded ANPs (two-tailed Wilcoxon test, * p = 0.0128 (5–10 s), **** p < 0.0001 (0–5 s), n = 4 mice). Data represented as mean ± SEM.

    Journal: Nature Communications

    Article Title: Development of a genetically encoded sensor for probing endogenous nociceptin opioid peptide release

    doi: 10.1038/s41467-024-49712-0

    Figure Lengend Snippet: a . Fiber photometry schematic. Cartoon of NOPLight viral injection and fiber implant in the VTA of WT mice ( n = 4 mice). Representative image showing expression of DAPI (blue) and NOPLight (green) with fiber placement in VTA. b . Left: Cartoon depicting operant box setup for the progressive ratio (PR) test. Right: Trial structure for reward delivery during the paradigm. c . Top: Averaged trace of NOPLight signal for all mice ( n = 4), aligned to rewarded active nose pokes (ANPs) made during the PR test. Epoch includes the 5 s light cue (yellow, shaded) that precedes reward delivery. Time to pellet retrieval and duration of consumption period averaged across all trials (brown, shaded). Data represented as mean ± SEM. Bottom: Heat map, each row corresponds to a single, rewarded ANP epoch. d Top: Averaged trace of NOPLight signal for all mice ( n = 4), aligned to non-rewarded ANPs made during the PR test. Data represented as mean ± SEM. Bottom: Heat map, each row corresponds to a single, non-rewarded ANP epoch. e NOPLight fluorescence averaged over 5-s intervals for rewarded (green) and non-rewarded (blue) ANP epochs. Time to pellet retrieval and duration of consumption period averaged across all rewarded trials (brown, shaded). Across rewarded ANP trials, NOPLight signal decreases during reward consumption then immediately increases post-consumption relative to NOPLight signal measured during non-rewarded ANP epochs (two-way repeated-measures ANOVA with Bonferroni’s post hoc test, * p = 0.0122, ** p = 0.0033, *** p = 0.0003, n = 4 mice). Data represented as mean ± SEM. f , g Area under the curve (AUC) for photometry traces from c and d , respectively, calculated over 5-s intervals surrounding ( f ) rewarded ANPs (two-tailed Wilcoxon test, * p = 0.0125 (25–30 s) or 0.031 (30–35 s); ** p = 0.007 (5–10 s) or 0.0042 (15–20 s); *** p = 0.0008 (10–15 s); n = 4 mice) and ( g ) non-rewarded ANPs (two-tailed Wilcoxon test, * p = 0.0128 (5–10 s), **** p < 0.0001 (0–5 s), n = 4 mice). Data represented as mean ± SEM.

    Article Snippet: Fluorescent signals were excited at 488 nm (NOPLight) and 561 nm (Red-Dextran dye) and recorded using the high-speed line-scan function (Zeiss LSM 800) at 800 Hz.

    Techniques: Injection, Expressing, Fluorescence, Two Tailed Test